SCHEMBL3598967

SCHEMBL3598967

CC(C)(C)OC(=O)N1CCN(CCN2c3ccccc3N(c3ccccc3Cl)S2(=O)=O)CC1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.47
THRB P10828 1/20 0.44
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
DRD2 P14416 2/20 0.42
DRD4 P21917 1/20 0.42
LMNA P02545 3/20 0.42
ACKR3 P25106 1/20 0.41
HTR7 P34969 1/20 0.41
MAPT P10636 3/20 0.41
TP53 P04637 2/20 0.41
TERT O14746 1/20 0.40
HTR1A P08908 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3598964 0.90 THRB (0.44) THRBCHRM2CHRM4CHRM1CHRM3
SCHEMBL3594835 0.89 SLC6A2 (0.46) SLC6A2CHRM2CHRM4CHRM1CHRM3
SCHEMBL4062477 0.88 SLC6A2 (0.50) SLC6A2THRBCHRM2CHRM4CHRM1
SCHEMBL4058421 0.88 SLC6A2 (0.48) SLC6A2CHRM2CHRM4CHRM1CHRM3
SCHEMBL4056547 0.85 SLC6A2 (0.43) SLC6A2THRBCHRM2CHRM4CHRM1
SCHEMBL3598865 0.84 CHRM2 (0.41) SLC6A2CHRM2CHRM4CHRM1CHRM3
SCHEMBL3608813 0.84 SLC6A2 (0.47) SLC6A2THRBCHRM2CHRM4CHRM1
SCHEMBL4056335 0.84 SLC6A2 (0.48) SLC6A2THRBCHRM2CHRM4CHRM1
SCHEMBL4053517 0.84 SLC6A2 (0.48) SLC6A2THRBCHRM2CHRM4CHRM1
SCHEMBL3616311 0.84 SLC6A2 (0.45) SLC6A2CHRM2CHRM4CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029641-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2010-02-04 US disclosed
US-7601722-B2 Aryl sulfamide derivatives and methods of their use WYETH (US) 2009-10-13 US disclosed
EP-2061776-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE Wyeth a Corporation of the State of Delaware (US) 2009-05-27 EP disclosed
US-20080167303-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-10 US disclosed
WO-2008073459-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029641-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE SLC6A4, SLC6A2, SLC6A3 SLC6A2 2/4885THRB 795/4885CHRM2 988/4885
US-20080167303-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE SLC6A4, SLC6A2, SLC6A3 SLC6A2 2/4885THRB 795/4885CHRM2 988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.